Market Minds Advisory
Progressive Fibrosing Interstitial Lung Disease (PFILD) Market

Progressive Fibrosing Interstitial Lung Disease (PFILD) Market: Treating a Behaviour Rather Than a Diagnosis, and Losing Patients to Tolerability

Antifibrotics slow lung scarring in dozens of different diseases that share one behaviour, and a quarter of patients stop taking them because of side effects nobody has managed to design out.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$4.2BMarket Size 2025
2036 FORECAST VALUE$12.7BBase Case , 2026 to 2036
CAGR 2026 TO 203610.6 %Bull 11.8% / Bear 9.4%
INCREMENTAL OPPORTUNITY$8.1BNet 10- year value creation
EXPANSION MULTIPLE2.74x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

This category treats a behaviour rather than a diagnosis. Dozens of interstitial lung diseases with different causes converge on the same progressive scarring, and the antifibrotics slow that scarring regardless of which underlying condition started it. The trials proved the behaviour matters more than the label.
Phosphodiesterase-4B inhibitors compound at 15.9%, exactly 1.50 times the market, because they promise antifibrotic benefit without the gastrointestinal burden driving current discontinuation. North America holds 32% of spend on antifibrotic pricing and specialist centre density. Roughly 24% of patients stop existing therapy on tolerability grounds alone. Antifibrotics slow forced vital capacity decline by roughly 57% across the whole progressive fibrosing group rather than only in the idiopathic form.
Five companies hold 71%, the highest concentration in respiratory medicine, because two molecules have carried the field for a decade. Diagnosis requires multidisciplinary review that most patients never receive, which caps the treated population well below prevalence. Only around 38% of suspected cases reach that review, and the interval from first symptoms averages 17 months. By then irreversible fibrosis has accumulated that nothing available reverses, which is the constraint the pipeline does not address.
Market Definition
The market covers therapeutics used to treat progressive fibrosing interstitial lung disease across idiopathic and secondary aetiologies, spanning tyrosine kinase antifibrotics, pyridone antifibrotics, phosphodiesterase-4B inhibitors, lysophosphatidic acid receptor antagonists, immunosuppressive and immunomodulatory therapy, and supportive symptomatic management. Long-term oxygen equipment, pulmonary rehabilitation services, lung transplantation surgery, diagnostic imaging and biopsy procedures, and treatment of underlying connective tissue disease outside the lung are excluded.
Base Year Value
$4.2B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
10.6% base case. Bull 11.8%. Bear 9.4%.
Fastest Growth Segment
Phosphodiesterase-4B Inhibitors: 15.9% CAGR
Fastest Growth Country
China: 12.4% CAGR
Fastest Growth Region
South Asia and Pacific: 12.7% CAGR
Largest Region
North America: 32% of 2025 global value
Market Leaders
Boehringer Ingelheim, Roche, Shionogi, Bristol Myers Squibb, Pliant Therapeutics. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Progressive Fibrosing Interstitial Lung Disease (PFILD) Market Forecast Scenarios

progressive-fibrosing-interstitial-lung-disease-pf-size-forecast-scenario-1787309185899
Growth of 9.2% across 2020 to 2025 came from broadening the definition rather than from new molecules. Antifibrotic therapy was licensed for idiopathic pulmonary fibrosis alone, and trial evidence then established benefit across fibrosing disease of any cause. Labels widened accordingly. What did not change was the diagnostic pathway: a patient still needed a multidisciplinary team to confirm progressive fibrosing behaviour, and most hospitals have no such team.
The base case of 10.6% rests on three mechanisms. Rheumatology is learning to screen for progressive lung involvement in connective tissue disease rather than waiting for symptoms, which converts prevalent undiagnosed disease into treated patients. Inhaled antifibrotic and prostacyclin approaches in late development promise the tolerability that oral therapy conspicuously lacks. And multidisciplinary team capacity is expanding across developed systems, which is the actual constraint on how many patients reach therapy at all.
The bull case of 11.8% assumes an inhaled therapy reaches approval with materially better tolerability, since roughly 34% of patients currently discontinue oral antifibrotics within a year for gastrointestinal reasons rather than lack of effect. The bear case of 9.3% reflects the persistent problem: multidisciplinary capacity grows slowly, rheumatology screening stays inconsistent, and payers require documented decline before funding.

One Behaviour, Many Diagnoses

The clinical insight underpinning this market is that the underlying disease matters less than what the lung is doing. Rheumatoid arthritis, systemic sclerosis, hypersensitivity pneumonitis, sarcoidosis and unclassifiable interstitial disease can all progress to the same self-sustaining fibrosis, and antifibrotics slow forced vital capacity decline by roughly 57% across that whole group rather than only in the idiopathic form. The label matters far less than the trajectory.
TOP FIVE CONCENTRATION71%Combined share held by the five largest participating companies
LUNG FUNCTION DECLINE SLOWED57%Reduction in annual forced vital capacity loss under therapy
DISCONTINUATION ON TOLERABILITY24% of patientsShare stopping therapy because of adverse effects rather than progression
ANNUAL THERAPY COSTUSD 94,000Median cost per treated patient across approved antifibrotic therapy
MULTIDISCIPLINARY REVIEW ACCESS38% of casesShare of suspected patients reaching formal multidisciplinary diagnostic review
DIAGNOSTIC INTERVAL17 monthsTypical delay from first respiratory symptoms to confirmed diagnosis
The commercial problem is that patients do not stay on the drugs. Around 24% discontinue on tolerability grounds, principally diarrhoea, nausea, weight loss and photosensitivity depending on which agent they receive, and discontinuation in a progressive disease means resumed decline. A therapy that works and that a quarter of patients abandon has a duration problem rather than an efficacy one.
Diagnosis is the other constraint. Confirming progressive fibrosing behaviour requires high-resolution imaging read alongside serology, exposure history and lung function trajectory, ideally in a multidisciplinary discussion. Only around 38% of suspected cases reach that review, and the interval from first symptoms averages 17 months, by which point irreversible fibrosis has accumulated that no therapy reverses. Referral behaviour rather than review capacity is usually the obstacle.
"We have spent a decade arguing about which interstitial lung disease a patient has, when the treatment decision turns on whether the fibrosis is progressing. The trials answered that question and the diagnostic pathways have not caught up."
Director, Respiratory and Fibrosis Therapeutics Practice · MMA Respiratory and F

Market Trends

New Mechanisms Target the Tolerability Problem Directly

Phosphodiesterase-4B inhibition and lysophosphatidic acid receptor antagonism both aim at antifibrotic effect without the gastrointestinal burden that drives around 24% of patients off current therapy. That is a duration argument rather than an efficacy one, and in a progressive disease duration is what determines outcome. The phosphodiesterase-4B segment compounds at 15.9% against a market at 10.6% on exactly that proposition, and the clinical rationale is more credible than most tolerability claims. Both are oral and both can be combined with existing antifibrotics. Both are being developed in populations that already carry a confirmed diagnosis rather than needing new ones found.
Market Impact: Review reaching only 38% of cases

Progressive Behaviour Replaces Diagnostic Label in Treatment Decisions

Trials demonstrating antifibrotic benefit across non-idiopathic progressive fibrosing disease shifted the treatment question from which interstitial lung disease a patient has to whether their fibrosis is progressing. That reframing opened rheumatoid, scleroderma-associated, hypersensitivity pneumonitis and unclassifiable populations to therapy, and it slows forced vital capacity decline by roughly 57% across all of them. Diagnostic pathways built around aetiological classification have not adapted to the change. Rheumatoid, scleroderma-associated, hypersensitivity pneumonitis and unclassifiable populations all became treatable on that basis, and they are collectively larger than the idiopathic population ever was. Referral pathways have not adapted.
Market Impact: Therapy priced at USD 94,000 annual

Market Opportunities and Growth Drivers

Secondary Aetiologies Enlarge the Treatable Population Substantially

Idiopathic pulmonary fibrosis was always a small population, and progressive fibrosing behaviour occurring across rheumatoid arthritis, systemic sclerosis, hypersensitivity pneumonitis, sarcoidosis and unclassifiable disease is considerably larger. Those patients sit under rheumatologists and general respiratory physicians rather than specialist interstitial lung disease clinics, which is both the opportunity and the obstacle. Reaching them requires a different commercial approach from the one built around a handful of academic referral centres. Only around 38% of suspected cases reach the multidisciplinary review that confirms progressive behaviour, so most of that larger population remains invisible to every company simultaneously.
Market Impact: Losing 24% to adverse effects

Antifibrotic Pricing Sustains Development Across Small Populations

Median annual therapy cost near USD 94,000 makes a population of tens of thousands commercially substantial, which is what has funded the pipeline now arriving. Orphan designation in the idiopathic form provided the initial economics, and label expansion across secondary aetiologies enlarged the population without any change in price. That combination has drawn serious developers into fibrosis after a long period in which almost nobody would fund a respiratory programme at all. Respiratory medicine went a long period in which almost nobody would fund a programme, and antifibrotic pricing is what reversed that.
Market Impact: Delay averaging 17 months to diagno

Market Restraints and Challenges

A Quarter of Patients Abandon Therapy That Works

Around 24% of patients discontinue on tolerability grounds rather than because the drug failed, and in a progressive disease stopping means resumed decline toward transplant or death. The root cause is that both established agents carry substantial gastrointestinal or photosensitivity burden at effective doses. Companies mitigate with dose reduction protocols, proactive symptom management and formulation work, and the pipeline is largely built around achieving similar efficacy without the same burden. The pipeline is largely built around achieving similar efficacy without the same burden, which is a duration argument rather than a potency one.
Market Impact: Addressing 24% discontinuation rate

Multidisciplinary Diagnosis Reaches a Minority of Patients

Confirming progressive fibrosing behaviour requires imaging, serology, exposure history and lung function trajectory reviewed together, and only around 38% of suspected cases reach that discussion. The root cause is that multidisciplinary review requires a radiologist, pathologist and respiratory physician in the same room, which most hospitals cannot assemble routinely. Companies mitigate by funding regional review networks, remote review platforms and referral criteria distributed to rheumatology and general respiratory practice. Remote review platforms are the practical answer, since they reach hospitals that cannot assemble three specialists in one room on any regular basis.
Market Impact: Decline slowed by 57% overall
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows therapeutic mechanism, because each acts on a different point in the fibrotic cascade and carries a different tolerability profile. In a disease where roughly a quarter of patients abandon effective therapy, mechanism determines duration as much as it determines efficacy. Six mechanisms sit in the hierarchy, separated by where each acts in the fibrotic cascade.
progressive-fibrosing-interstitial-lung-disease-pf-market-share-analysis-1787309186439

Phosphodiesterase-4B Inhibitors

Phosphodiesterase-4B inhibition compounds at 15.9%, exactly 1.50 times the market, and the argument is tolerability rather than superior efficacy. Selective 4B inhibition targets the antifibrotic and anti-inflammatory pathway while avoiding much of the emetic effect that limited earlier broad phosphodiesterase-4 inhibitors, which matters enormously when 24% of patients currently abandon therapy on gastrointestinal grounds. In a progressive disease, a drug patients continue taking outperforms a marginally more potent one they stop. Oral dosing, combination potential alongside existing antifibrotics and applicability across both idiopathic and secondary progressive fibrosing populations all support the position. Payer willingness to fund combination regimens at these prices remains the open question rather than the clinical case.
CAGR 15.9%

Lysophosphatidic Acid Receptor Antagonists

Lysophosphatidic acid receptor antagonism grows at 14.2% by blocking a signalling pathway that drives fibroblast recruitment and differentiation, upstream of the collagen deposition that established antifibrotics slow. The mechanism has a coherent biological rationale and a difficult history, since an autotaxin inhibitor targeting the same pathway failed convincingly in late-stage development, which the field has not forgotten. Selective receptor antagonism is a different proposition from enzyme inhibition and the current programmes reflect that learning. Oral administration and an apparently manageable tolerability profile support the duration argument that matters most here. Combination use alongside a tyrosine kinase antifibrotic is where the commercial opportunity concentrates rather than in monotherapy. Monotherapy positioning would be considerably harder to defend.
CAGR 14.2%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Demand follows antifibrotic pricing and diagnostic capability together, since a patient generates revenue only where multidisciplinary review has confirmed progressive fibrosing behaviour and a payer funds the therapy. North America leads on realised pricing rather than on any epidemiological concentration of disease. Diagnosis caps everything.

North America

North America holds 32% of spend, the largest regional share, growing at 10.3%. The reason is pricing and infrastructure rather than epidemiology, and it is worth saying plainly: antifibrotic pricing near USD 94,000 annually is realised most fully here, and designated interstitial lung disease centres with functioning multidisciplinary review are denser than anywhere else. Rheumatology-referred progressive fibrosing disease is recognised more consistently as a result. Clinical trial activity is concentrated in the region, which also means new mechanisms reach patients here first through study participation well before approval. Rheumatology referral remains the largest untapped population even here, because those patients sit outside the specialist interstitial lung disease clinics where recognition is strongest.
Share: 32% | CAGR: 10.3% (2026 to 2036)

Western Europe

Twenty-six percent of spend sits in Western Europe, growing at 8.9%, the slowest of the seven regions. European respiratory medicine produced much of the foundational work on progressive fibrosing behaviour, and reference centre networks make multidisciplinary review more systematic than the global average. Health technology assessment scrutiny of antifibrotic pricing is rigorous, and several markets fund therapy only after documented progression rather than at diagnosis. That requirement is clinically defensible and it costs patients months of decline, which is a genuine tension nobody has resolved. Reference centre networks make multidisciplinary review considerably more systematic than the global average, which partly offsets the funding restrictions applied on top of it. That tension is genuine and unresolved.
Share: 26% | CAGR: 8.9% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
progressive-fibrosing-interstitial-lung-disease-pf-country-cagr-analysis-1787309186959

Keeping Patients on Therapy Longer

Efficacy in this field is broadly established and duration is not, since a quarter of patients stop taking drugs that work. Four positions matter, and two of them are about diagnosis and persistence rather than about any molecule a company owns. The other two concern prescriber reach and payer preparation, and none of the four turns on effect size.

Compete on Persistence Rather Than Potency

Around 24% of patients discontinue on tolerability grounds, and in a progressive disease stopping therapy means resumed decline toward transplant. A drug patients continue taking outperforms a marginally more potent one they abandon, which is the entire argument behind phosphodiesterase-4B inhibition compounding at 15.9%. Companies that measure and report persistence alongside forced vital capacity endpoints reframe the comparison onto ground where the newer mechanisms genuinely win rather than merely claim to. Efficacy is broadly settled and duration is the open question. Persistence data is what differentiates a newer mechanism credibly.
Market Impact: Recovering the 24% who now disconti

Fund Multidisciplinary Review Access Beyond Academic Centres

Only around 38% of suspected cases reach the multidisciplinary discussion that confirms progressive fibrosing behaviour, and the diagnostic interval averages 17 months. Funding regional review networks and remote review platforms converts undiagnosed patients into treated ones, which expands the market rather than redistributing it. The company funding that infrastructure is present when the diagnosis is made, which matters more in a field this concentrated than any promotional activity ever does. The diagnostic interval averages 17 months of accumulating irreversible fibrosis. Expanding the market beats redistributing it. Presence at the point of diagnosis matters more than promotion.
Market Impact: Review reaching only 38% of all sus

Reach Rheumatology and General Respiratory Prescribers

Progressive fibrosing behaviour in rheumatoid arthritis, systemic sclerosis and hypersensitivity pneumonitis is a considerably larger population than idiopathic disease, and those patients sit under rheumatologists and general respiratory physicians rather than specialist interstitial lung disease clinics. Commercial models built around a handful of academic referral centres reach almost none of them. Referral criteria naming progressive behaviour explicitly, distributed to those specialties, is the mechanism that works at therapy priced near USD 94,000 annually. Those specialties think about the lung as one manifestation among several rather than as the primary problem.
Market Impact: Therapy priced near USD 94,000 in e

Prepare the Combination Regimen Payer Argument Early

The newer mechanisms are most likely to be used alongside existing antifibrotics rather than instead of them, which doubles the annual cost from a median already near USD 94,000. Payers have not yet indicated what they will fund for combination therapy in this disease. Companies generating comparative and additive benefit data during registration, rather than after launch, arrive at that negotiation with evidence instead of a pricing proposal, and the sequencing matters enormously. Arriving with evidence rather than a pricing proposal is the whole point. No payer has yet said what it would fund.
Market Impact: Combinations doubling that USD 94,0

Who Controls the Margin Pool

Five companies hold 71% measured on progressive fibrosing interstitial lung disease therapeutic revenue, the basis applied throughout this section. That is the highest concentration in respiratory medicine and it reflects a decade in which two molecules carried the entire field. Boehringer Ingelheim and Roche between them account for most of it, and the challenger group is almost entirely pipeline rather than revenue.
Competition operates on three dimensions. Tolerability and persistence decide whether patients stay on therapy long enough to benefit. Diagnostic infrastructure presence decides who is there when progressive behaviour is confirmed. And prescriber reach beyond specialist interstitial lung disease centres decides access to the secondary aetiology populations that are larger than the idiopathic one. Lung function effect size decides less than any of the three.

The field is about to change more than it has in a decade. Phosphodiesterase-4B inhibition and lysophosphatidic acid receptor antagonism both address the discontinuation problem the incumbents never solved. Rankings will shift toward whoever demonstrates persistence advantage and secures combination reimbursement rather than whoever shows the largest lung function effect. Owning both an incumbent and its successor is a rare and awkward position.
progressive-fibrosing-interstitial-lung-disease-pf-company-positioning-matrix-1787309187486

Competitive Moat and Risk Dimensions

BOEHRINGER INGELHEIM

Moat: Label breadth and pipeline position

Boehringer Ingelheim holds the broadest antifibrotic label across idiopathic and secondary progressive fibrosing disease, having funded the trials that established the behaviour-based treatment rationale, and it is also developing the leading phosphodiesterase-4B inhibitor. Owning both the incumbent and the most credible successor is a rare position that lets the company manage its own transition rather than defend against somebody else's.
BOEHRINGER INGELHEIM

Risk: Incumbent tolerability burden

The established agent carries the gastrointestinal burden driving much of the 24% discontinuation rate, and every competitor entering with a better-tolerated mechanism attacks precisely that weakness. Defending the incumbent while launching the successor requires the company to make an argument against its own product, which is commercially awkward and clinically unavoidable.
ROCHE

Moat: Established antifibrotic prescriber base

Roche holds deep prescriber familiarity across respiratory and interstitial lung disease practice built over a decade of pirfenidone use, together with the real-world persistence and dose management experience that comes with it. In a field where clinicians manage tolerability actively rather than switching, that accumulated practical knowledge holds patients on therapy in a way trial data alone does not.
ROCHE

Risk: Generic erosion and pipeline gap

Pirfenidone faces generic competition that has already reduced pricing substantially in India and elsewhere, and Roche holds no comparably advanced position in the newer antifibrotic mechanisms. A franchise eroding on price while the therapeutic frontier moves to a mechanism the company does not own is the most exposed position among the current leaders.

Players Tracked

Prominent Players

Boehringer Ingelheim
Roche
Shionogi
Bristol Myers Squibb
Pliant Therapeutics

Other Key Players

Sanofi
AstraZeneca
Merck & Co
Galapagos
FibroGen
Avalyn Pharma
Vicore Pharma
PureTech Health
Cipla
Sun Pharmaceutical Industries
Natco Pharma
Zydus Lifesciences
Alkem Laboratories
Nippon Shinyaku
Kyorin Pharmaceutical

Recent Developments

JANUARY 2025

Phosphodiesterase-4B inhibition reports positive late-stage fibrosis results

Late-stage trials of selective phosphodiesterase-4B inhibition in pulmonary fibrosis reported preserved lung function with a tolerability profile distinct from established antifibrotics. These were clinical trial outcomes rather than commercial developments among the companies conducting them. Combination use alongside existing antifibrotics was the positioning implied throughout.
Signal: A tolerability advantage in a progressive
JUNE 2025

Reimbursement bodies require documented progression before funding therapy

Several European payers formalised requirements for documented lung function decline before funding antifibrotic therapy in secondary progressive fibrosing disease, rather than treating at diagnosis. These were reimbursement policy decisions rather than clinical guideline changes or corporate developments. Clinicians have objected that waiting for documented decline wastes irreversible lung function.
Signal: Requiring documented decline before fundin
OCTOBER 2025

Remote multidisciplinary review networks extend diagnostic access

Regional respiratory networks established remote multidisciplinary review platforms allowing radiologists, pathologists and respiratory physicians to assess interstitial lung disease cases without co-location. This reflects clinical service design rather than any transaction among therapeutic companies. Referring hospitals participate without transferring the patient anywhere, which removes the main practical obstacle.
Signal: Remote review reaches exactly those patien

Small Molecule Synthesis and Trial Scale

Active ingredient synthesis and formulation account for roughly 14% of cost of goods, which is low because these are oral small molecules manufactured at modest volume against very high realised pricing. Packaging, distribution and pharmacovigilance add about 9%. The dominant economic burden sits entirely outside cost of goods, in registrational trials requiring lung function endpoints measured over a year or more across many sites.
Active ingredient intermediate supply tightened through 2021 and 2022 as pharmaceutical chemical manufacturing capacity was reallocated, and antifibrotic producers absorbed it without difficulty because ingredient cost is a small fraction of realised price. Company annual reports across the respiratory developers disclose that trial and commercial spend rather than manufacturing dominate the cost base. World Health Organization reporting on essential medicine supply documents intermediate manufacturing concentration.

Exposure divides by pricing position rather than by manufacturing. Originators carry trial and commercial cost against pricing near USD 94,000 annually, so input movement is immaterial. Generic pirfenidone producers in India and elsewhere operate at a fraction of that price, where ingredient and manufacturing cost matter considerably. Developers of new mechanisms carry the full trial burden against no revenue at all, which is the hardest position of the three.
progressive-fibrosing-interstitial-lung-disease-pf-cost-volatility-analysis-1787309187681

Design registrational trials with persistence endpoints included

Adding treatment persistence and discontinuation reasons to a registrational programme costs very little against a trial already measuring lung function over a year, and it produces the evidence that differentiates a better-tolerated mechanism. Generating it afterwards means a separate study and a launch spent arguing tolerability without data to support the claim. Very few programmes have done it.

Build combination benefit evidence before payers demand it

New mechanisms will mostly be used alongside existing antifibrotics rather than replacing them, which doubles annual cost from a base near USD 94,000. Payers have not yet said what they will fund. Generating additive benefit data during registration rather than afterwards means arriving with evidence rather than a pricing proposal at the moment it matters most.

Fund diagnostic infrastructure as market development spend

Only around 38% of suspected cases reach multidisciplinary review, so a large share of the addressable population is invisible to every company in the field simultaneously. Classifying regional review network funding as market development rather than promotional spend protects it from commercial review cuts and puts the honest economics in front of leadership. The economics are honest either way.

Portfolio Architecture for Margin Defence

The portfolio separates on mechanism and on where each sits relative to the fibrotic cascade. Tyrosine kinase and pyridone antifibrotics slow collagen deposition and carry the tolerability burden that defines the category's weakness. Phosphodiesterase-4B inhibition and lysophosphatidic acid antagonism act further upstream with better tolerability. Immunosuppression treats the inflammatory component in secondary aetiologies. Supportive management addresses symptoms without altering trajectory. Ge
The tension is between established efficacy and unproven duration. The incumbents have a decade of real-world experience and a discontinuation problem. The new mechanisms have credible tolerability arguments and no long-term outcome data, and their most likely use is in combination, which doubles cost against payers who have not agreed to fund it. Neither position is comfortable.

High-value pools concentrate where duration improves. New mechanisms with persistence data, combination regimens with additive benefit evidence, and any position built on diagnostic infrastructure presence all qualify, and none of them is decided on lung function effect size alone. What they share is that the patient stays on therapy longer, which in a progressive disease is simultaneously the clinical outcome and the commercial one.

Volume / Commodity-Adjacent Tier

Supportive symptomatic management and generic pyridone antifibrotic supply at a fraction of originator pricing. Widely available across price-sensitive markets, unable to alter disease trajectory in the first case and heavily eroded on price in the second.
Gross Margin: 18-34%

Premium / Certified Tier

Established tyrosine kinase and branded pyridone antifibrotics with a decade of real-world dose management experience. Efficacy is proven across idiopathic and secondary progressive disease, and tolerability burden remains the defining commercial weakness.
Gross Margin: 70-82%

Sustainability / Regulatory / Next-Generation Tier

Phosphodiesterase-4B inhibitors and lysophosphatidic acid receptor antagonists competing on persistence rather than potency. The wide margin range separates approved products from programmes still carrying full development cost against no revenue whatsoever.
Gross Margin: 40-86%
progressive-fibrosing-interstitial-lung-disease-pf-portfolio-architecture-1787309188185

High-value Sub-segments and Strategic Watch-out

Phosphodiesterase-4B Inhibitors

Compounding at 15.9% on a tolerability argument that addresses the 24% discontinuation rate directly rather than claiming superior potency. Combination use alongside existing antifibrotics is the likely position, and payer willingness to fund it remains unresolved. Oral dosing and combination potential both support the position.
Gross Margin: 62-86%

Lysophosphatidic Acid Antagonists

Growing at 14.2% by blocking fibroblast recruitment upstream of collagen deposition, with a coherent rationale and a difficult history the field remembers. Selective receptor antagonism differs meaningfully from the enzyme inhibition that failed before it. Combination alongside a tyrosine kinase antifibrotic is where the opportunity sits.
Gross Margin: 40-78%

Established Tyrosine Kinase Antifibrotics

The clinical core at 8.4%, slowing lung function decline by roughly 57% across both idiopathic and secondary progressive disease. Gastrointestinal tolerability is the persistent weakness, and every new entrant attacks precisely that point. A decade of real-world dose management experience still counts for a great deal.
Gross Margin: 70-82%

Immunosuppressive and Immunomodulatory Therapy

The strategic watch-out here. Treating the inflammatory component in secondary aetiologies remains entirely standard practice across rheumatology, and the evidence for any real benefit once the fibrosis has become self-sustaining is genuinely weak rather than merely incomplete. Prescribing habit rather than trial data sustains it.
Gross Margin: 24-52%

Lifelong Therapy Interrupted by Side Effects

Revenue should be lifelong annuity and frequently is not. A patient with confirmed progressive fibrosing disease requires antifibrotic therapy indefinitely, at a median near USD 94,000 annually, and the disease provides no reason to stop. Around 24% stop anyway on tolerability grounds, which converts what should be a decade of revenue into a year or two and delivers a worse outcome for the patient simultaneously.
Depth varies by aetiology and by who manages the patient. Idiopathic pulmonary fibrosis patients under specialist interstitial lung disease clinics are treated earliest and monitored most closely. Systemic sclerosis and rheumatoid patients under rheumatology are recognised later and treated less consistently. Hypersensitivity pneumonitis patients require exposure removal alongside therapy. Unclassifiable disease patients are frequently treated only after substantial decline.

The deciding clinician differs sharply by aetiology, which shapes everything commercially. Specialist interstitial lung disease physicians manage the idiopathic population and are few enough to know individually. Rheumatologists manage a larger secondary population and think about the lung as one manifestation among several. General respiratory physicians see the unclassifiable cases and refer inconsistently, which is where most of the undiagnosed population sits.
progressive-fibrosing-interstitial-lung-disease-pf-end-use-penetration-index-1787309188682

Where Developers Build Position

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / TREATMENT PERSISTENCE ADVANTAGE

A drug patients stop taking loses to one they tolerate

Around 24% of patients discontinue antifibrotic therapy on tolerability grounds rather than because it failed, and in a progressive disease stopping treatment means resumed decline toward transplant or toward death. Persistence therefore determines outcome as much as potency does, which is the entire argument behind phosphodiesterase-4B inhibition compounding at 15.9%. Companies that measure and report persistence alongside conventional lung function endpoints compete on ground where the newer mechanisms genuinely win, rather than on effect size where the incumbents remain perfectly competitive.
02 / DIAGNOSTIC NETWORK INVESTMENT

Three specialists in one room is the actual bottleneck

Confirming progressive fibrosing behaviour needs imaging, serology, exposure history and lung function trajectory assessed together, and only around 38% of suspected cases reach that discussion. The diagnostic interval averages 17 months of accumulating irreversible fibrosis. Funding regional and remote review networks converts invisible patients into treated ones and expands the market rather than redistributing it, while putting the funding company in the room when each diagnosis is finally made, which matters more in a field this concentrated than any promotional activity does.
03 / SECONDARY AETIOLOGY REACH

The larger population sits under rheumatologists, not respiratory

Progressive fibrosing behaviour across rheumatoid arthritis, systemic sclerosis, hypersensitivity pneumonitis and unclassifiable disease is a substantially larger population than idiopathic pulmonary fibrosis ever was, and those patients are managed outside specialist interstitial lung disease clinics entirely. Commercial models built around specialist academic referral centres reach almost none of that population at all. Referral criteria naming progressive fibrosing behaviour explicitly, distributed directly to rheumatology and general respiratory practice, is what actually works, and almost nobody has distributed those criteria to rheumatology at all.
04 / COMBINATION ACCESS PREPARATION

Two antifibrotics means twice a very large number

The newer mechanisms will mostly be added to existing antifibrotics rather than replacing them, which doubles annual cost from a median already near USD 94,000, and no payer anywhere has yet indicated what it will fund for combination therapy in this disease. Generating additive benefit data during registration rather than after launch means arriving at that negotiation carrying evidence instead of a pricing proposal. The sequencing of that evidence matters considerably more than the number that eventually gets attached to it.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Progressive Fibrosing Interstitial Lung Disease (PFILD) Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Progressive Fibrosing Interstitial Lung Disease (PFILD) Exposure Evaluation 2025-26
CLIENT PROFILE
A respiratory network of eleven hospitals serving roughly 3.4 million people, with one designated interstitial lung disease centre running multidisciplinary review and ten general respiratory services referring into it (client-reported, unverified by MMA). Antifibrotic prescribing volumes sat well below what regional prevalence estimates predicted, and leadership assumed under-diagnosis somewhere in the pathway. Referral behaviour had never been audited by specialty.
STRATEGIC CHALLENGE
Referral volumes into multidisciplinary review had been flat for three years while the designated centre reported spare review capacity. Attention had focused on whether general respiratory physicians were recognising interstitial disease at all. Nobody had examined where patients with confirmed interstitial lung disease were being managed, or whether rheumatology was referring anybody.
MMA APPROACH
MMA traced all patients with a recorded interstitial lung disease diagnosis across the eleven hospitals over three years, identifying who had reached multidisciplinary review, who had received antifibrotic therapy, and which specialty had been managing them at each point in the pathway. Referral rates were then calculated separately for general respiratory medicine and for rheumatology across the whole period.
KEY FINDINGS
  1. Forty-one percent of patients with recorded interstitial lung disease had reached multidisciplinary review, and almost none of the remainder had been referred despite meeting local criteria for it.
  2. Rheumatology had referred four patients across three years despite managing over 300 with connective tissue disease and documented interstitial lung involvement on imaging.
  3. The designated centre's spare review capacity was genuine, which eliminated capacity as an explanation and pointed the problem squarely at referral behaviour instead.
  4. Median interval from first abnormal imaging to multidisciplinary review was 19 months among referred patients, and lung function had declined measurably in most of that period.
CLIENT PROFILE
A respiratory network of eleven hospitals serving roughly 3.4 million people, with one designated interstitial lung disease centre running multidisciplinary review and ten general respiratory services referring into it (client-reported, unverified by MMA). Antifibrotic prescribing volumes sat well below what regional prevalence estimates predicted, and leadership assumed under-diagnosis somewhere in the pathway. Referral behaviour had never been audited by specialty.
STRATEGIC CHALLENGE
Referral volumes into multidisciplinary review had been flat for three years while the designated centre reported spare review capacity. Attention had focused on whether general respiratory physicians were recognising interstitial disease at all. Nobody had examined where patients with confirmed interstitial lung disease were being managed, or whether rheumatology was referring anybody.
MMA APPROACH
MMA traced all patients with a recorded interstitial lung disease diagnosis across the eleven hospitals over three years, identifying who had reached multidisciplinary review, who had received antifibrotic therapy, and which specialty had been managing them at each point in the pathway. Referral rates were then calculated separately for general respiratory medicine and for rheumatology across the whole period.
KEY FINDINGS
  1. Forty-one percent of patients with recorded interstitial lung disease had reached multidisciplinary review, and almost none of the remainder had been referred despite meeting local criteria for it.
  2. Rheumatology had referred four patients across three years despite managing over 300 with connective tissue disease and documented interstitial lung involvement on imaging.
  3. The designated centre's spare review capacity was genuine, which eliminated capacity as an explanation and pointed the problem squarely at referral behaviour instead.
  4. Median interval from first abnormal imaging to multidisciplinary review was 19 months among referred patients, and lung function had declined measurably in most of that period.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (months 1 to 4): Issue explicit referral criteria naming progressive fibrosing behaviour to rheumatology and all general respiratory services. Phase 2: Phase 2 (months 4 to 12): Establish remote multidisciplinary review sessions so that referring hospitals participate without transferring the patient. Phase 3: Phase 3 (months 12 to 22): Audit interstitial lung disease coding across rheumatology and build automatic review flags into imaging reports.
OUTCOME
Referrals into multidisciplinary review rose by approximately 140% within ten months, with rheumatology accounting for a third of the increase (client-reported, unverified by MMA). Median interval from abnormal imaging to review fell to eleven months (client-reported, unverified by MMA). Antifibrotic prescribing volumes roughly doubled and now sit closer to regional prevalence estimates than to the previous baseline.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Progressive Fibrosing Interstitial Lung Disease (PFILD) Market?

The global market was worth USD 4.2 billion in 2025, reaching USD 4.65 billion in 2026. North America holds the largest regional share at 32% of spend.

How large will the Progressive Fibrosing Interstitial Lung Disease (PFILD) Market be by 2036?

MMA forecasts USD 12.72 billion by 2036, an expansion multiple of 2.74 times the 2026 base. That represents roughly USD 8.07 billion of incremental value.

What is the CAGR for the Progressive Fibrosing Interstitial Lung Disease (PFILD) Market 2026 to 2036?

The base case compounds at 10.6% annually, with a bull case of 11.8% and a bear case of 9.4%. Historical growth from 2020 to 2025 ran at 9.2%.

Which segment is growing fastest?

Phosphodiesterase-4B inhibitors compound at 15.9%, exactly 1.50 times the market rate. Better tolerability rather than superior potency is the argument driving that entire growth rate.

Who are the major companies in the Progressive Fibrosing Interstitial Lung Disease (PFILD) Market?

Boehringer Ingelheim, Roche, Shionogi, Bristol Myers Squibb and Pliant Therapeutics hold a combined 71% of the market. Two molecules carried the entire field for a decade.

Which country is growing fastest?

China compounds at 12.4%, ahead of every other national market. Improving diagnosis beyond tier one hospitals and national reimbursement inclusion together drive that growth forward.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Therapeutic Mechanism

  • Tyrosine Kinase Antifibrotics
  • Pyridone Antifibrotics
  • Phosphodiesterase-4B Inhibitors
  • Lysophosphatidic Acid Receptor Antagonists
  • Immunosuppressive and Immunomodulatory Therapy
  • Supportive and Symptomatic Management

By End-Use Industry

  • Specialist Interstitial Lung Disease Centres
  • Rheumatology and Connective Tissue Disease Services
  • General Respiratory Medicine
  • Occupational and Environmental Lung Disease Services
  • Lung Transplant Programmes

By Commercial Dimension

  • Designated Centre and Specialist Supply
  • Reimbursed Retail and Specialty Pharmacy
  • Named Patient and Expanded Access Programmes
  • Generic and Price-Sensitive Market Supply

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The market covers therapeutics used to treat progressive fibrosing interstitial lung disease across idiopathic and secondary aetiologies, spanning tyrosine kinase antifibrotics, pyridone antifibrotics, phosphodiesterase-4B inhibitors, lysophosphatidic acid receptor antagonists, immunosuppressive and immunomodulatory therapy, and supportive symptomatic management, together with the diagnostic review infrastructure funded alongside them. Long-term oxygen equipment and services, pulmonary rehabilitation programmes, lung transplantation surgery and post-transplant immunosuppression, diagnostic imaging and biopsy procedures, and treatment of underlying connective tissue disease outside the lung are excluded. Sizing is measured at manufacturer revenue in current prices.
Quantitative Units
USD billions (current prices); treated patient counts, forced vital capacity decline rates and persistence duration where applicable
Segmentation Dimensions
By Therapeutic Mechanism; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Germany, Japan, France, UK, Italy, Spain, Canada, China, South Korea, Taiwan, India, Australia, Brazil, Mexico, Argentina, Colombia, Netherlands, Sweden, Denmark, Switzerland, Turkey, Israel, Saudi Arabia, UAE, South Africa, Poland, Czech Republic, Hungary, Thailand, and additional markets relevant to this sector
Key Companies Profiled
Boehringer Ingelheim, Roche, Shionogi, Bristol Myers Squibb, Pliant Therapeutics, Sanofi, AstraZeneca, Merck & Co, Galapagos, FibroGen, Avalyn Pharma, Vicore Pharma, PureTech Health, Cipla, Sun Pharmaceutical Industries, Natco Pharma, Zydus Lifesciences, Alkem Laboratories, Nippon Shinyaku, Kyorin Pharmaceutical
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-941
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Progressive Fibrosing Interstitial Lung Disease (PFILD) Market Report (2026 to 2036).

The full report sizes progressive fibrosing interstitial lung disease therapeutics across six mechanisms, three commercial dimensions and seven regions, with annual forecasts to 2036 under base, bull and bear scenarios. Treatment persistence and discontinuation reasons are compiled by agent and aetiology, which determines realised revenue duration far more than efficacy data does. Multidisciplinary review access and diagnostic intervals are measured by country and referring specialty. Reimbursement conditions requiring documented progression are mapped by payer. Twenty participating companies are profiled on a consistent antifibrotic therapeutic revenue basis.
Treatment persistence and discontinuation compiled by agent and aetiology
Multidisciplinary review access measured by country and referring specialty
Reimbursement progression requirements mapped across major payers
Secondary aetiology populations quantified against idiopathic disease
Combination regimen cost scenarios modelled against payer thresholds
Generic pyridone pricing tracked across price-sensitive markets

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts